Kidney cancer, version 3.2015: Featured updates to the NCCN guidelines

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 13, Issue 2, 2015, Pages 151-159

  Motzer, Robert J ^a   Jonasch, Eric ^b   Agarwal, Neeraj ^c   Beard, Clair ^d   Bhayani, Sam ^e   Bolger, Graeme B ^f   Chang, Sam S ^g   Choueiri, Toni K ^d   Costello, Brian A ^h   Derweesh, Ithaar H ⁱ   Gupta, Shilpa ^j   Hancock, Steven L ^k   Kim, Jenny J ^l   Kuzel, Timothy M ^m   Lam, Elaine T ⁿ   Lau, Clayton ^o   Levine, Ellis G ^p   Lin, Daniel W ^q   Michaelson, M Dror ^r   Olencki, Thomas ^s   Pili, Roberto ^p   Plimack, Elizabeth R ^t   Rampersaud, Edward N ^u   Redman, Bruce G ^v   Ryan, Charles J ^w   Sheinfeld, Joel ^a   Shuch, Brian ^x   Sircar, Kanishka ^b   Somer, Brad ^y   Wilder, Richard B ^j   Dwyer, Mary ^z   Kumar, Rashmi ^z   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d DANA FARBER BRIGHAM AND WOMEN S CANCER CENTER   (United States)

^e Washington University in St Louis School of Medicine   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g VANDERBILT INGRAM CANCER CENTER   (United States)

^h MAYO CLINIC CANCER CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^j H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^k STANFORD CANCER INSTITUTE   (United States)

^l JOHNS HOPKINS UNIVERSITY   (United States)

^m NORTHWESTERN UNIVERSITY   (United States)

ⁿ University of Colorado Cancer Center   (United States)

^o CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^p ROSWELL PARK CANCER INSTITUTE   (United States)

^q SEATTLE CANCER CARE ALLIANCE   (United States)

^r MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^s OHIO STATE UNIVERSITY   (United States)

^t FOX CHASE CANCER CENTER   (United States)

^u DUKE CANCER INSTITUTE   (United States)

^v UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^w UNIVERSITY OF CALIFORNIA   (United States)

^x YALE CANCER CENTER   (United States)

^y UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^z National Comprehensive Cancer Network   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; PAZOPANIB; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ABLATION THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CLINICAL DECISION MAKING; COMPUTER ASSISTED TOMOGRAPHY; CONTINUING EDUCATION; DISEASE SURVEILLANCE; FOLLOW UP; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; NEPHRECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PRACTICE GUIDELINE; REVIEW; CARCINOMA, RENAL CELL; KIDNEY NEOPLASMS;

CARCINOMA, RENAL CELL; HUMANS; IMIDAZOLES; INDAZOLES; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SULFONAMIDES;

EID: 84923445330     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2015.0022     Document Type: Review

References (13)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29
2. SEER Stat Fact Sheets: Kidney and Renal Pelvis Cancer. Available at: http:// seer.cancer.gov/statfacts/html/kidrp.html. Accessed January 20, 2015
3. Hutson TE, Lesovoy V, Al-Shukri S, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: A randomised openlabel phase 3 trial. Lancet Oncol 2013;14:1287-1294
4. Rini BI, Melichar B, Ueda T, et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: A randomised double-blind phase 2 trial. Lancet Oncol 2013;14:1233-1242
5. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 2010;28:1061-1068
6. Hainsworth JD, Rubin MS, Arrowsmith ER, et al. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: A Sarah Cannon Oncology Research Consortium phase II trial. Clin Genitourin Cancer 2013;11:270-275
7. Matrana MR, Duran C, Shetty A, et al. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur J Cancer 2013;49:3169-3175
8. Stewart SB, Thompson RH, Psutka SP, et al. Evaluation of the National Comprehensive Cancer Network and American Urological Association Renal Cell Carcinoma Surveillance guidelines. J Clin Oncol 2014;32:4059-4065
9. Mucksavage P, Kutikov A, Magerfleisch L, et al. Comparison of radiographical imaging modalities for measuring the diameter of renal masses: Is there a sizeable difference? BJU Int 2011;108:E232-236
10. Gill IS, Kavoussi LR, Lane BR, et al. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol 2007;178:41-46
11. Herr HW. Partial nephrectomy for incidental renal cell carcinoma. Br J Urol 1994;74:431-433
12. Morgan WR, Zincke H. Progression and survival after renal-conserving surgery for renal cell carcinoma: experience in 104 patients and extended followup. J Urol 1990;144:852-857
13. Adamy A, Chong KT, Chade D, et al. Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinoma. J Urol 2011;185:433-438.